505799790 12/03/2019

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5846619

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
ROCHE DIABETES CARE GMBH	11/27/2019

RECEIVING PARTY DATA

Name:	ROCHE DIABETES CARE, INC.	
Street Address:	9115 HAGUE ROAD	
City:	INDIANAPOLIS	
State/Country:	INDIANA	
Postal Code:	46250	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	15754756

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: docketdept@uspatent.com

Correspondent Name: WOODARD EMHARDT HENRY REEVES & WAGNER LLP

Address Line 1: 111 MONUMENT CIRCLE

Address Line 2: SUITE 3700

Address Line 4: INDIANAPOLIS, INDIANA 46204

ATTORNEY DOCKET NUMBER:	7804-72
NAME OF SUBMITTER:	MARY MOTYKA
SIGNATURE:	/mary motyka/
DATE SIGNED:	12/03/2019

Total Attachments: 1

source=assignmentrdcgtordci#page1.tif

PATENT 505799790 REEL: 051159 FRAME: 0842

PATENT APPLICATION ASSIGNMENT

WHEREAS, Roche Diabetes Care GmbH ("ASSIGNOR"), a corporation of Germany, having its principal office at Sandhofer Strasse 116, 68305 Mannheim, Germany, owns U.S. Patent Application Serial No. <u>15/754,756</u> filed <u>February 23, 2018</u>, entitled <u>KIT FOR DETERMINING AN ANALYTE CONCENTRATION</u>; and

WHEREAS, Roche Diabetes Care, Inc. ("ASSIGNEE"), a Delaware corporation, having its principal office at 9115 Hague Road, Indianapolis, Indiana 46250, United States of America, desires to acquire the entire right, title and interest in the Application;

NOW, THEREFORE, for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR hereby assigns, sells and transfers all rights, title and interest in the Application, including any divisions, continuations, continuations-in-part, reexaminations, reissues, extensions, or other U.S. patent applications claiming the benefit of the filing date of the Application, to ASSIGNEE, its successors and assigns.

ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks to issue any United States Letters Patent which may issue for the Application, including any divisions, continuations, continuations-in-part, reexaminations, reissues or extensions thereof, to ASSIGNEE, its successors and assigns.

ASSIGNOR does hereby covenant and agree with ASSIGNEE, its successors and assigns, that ASSIGNOR will not execute any writing or do any act conflicting with this assignment, and that ASSIGNOR will execute such additional writings and do such additional acts as ASSIGNEE, its successors and assigns, may deem necessary or desirable to perfect its enjoyment of this assignment, and render all necessary assistance in making application for and obtaining original, divisional, continuation, continuation-in-part, reissued, reexamined or extended Letters Patent of the United States of America that may issue from the Application.

Date:	2 7. NOV. 2019	Roche Diabetes Care GmbH Ppa . Signature:
		Printed Name: <u>Dr. Ferenc Molnar</u> Title: <u>Vice President</u>
Date:	2 7. NOV. 2019	Signature:
		Printed Name: Dr. Harald von Campenhauser Title: Qirector

PO16DER

RECORDED: 12/03/2019